Lercanidipine in patients with chronic renal failure: the ZAFRA Study
Aim. To evaluate the safe use of a new calcium channel blocker, lercanidipine, in patients with chronic renal failure (CRF); the protective effect of calcium channel blocker on renal function in CRF patients previously treated with ACE inhibitors or angiotensin receptor blockers (ARB). Material and...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2010-08-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/2108 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850028240049012736 |
|---|---|
| author | N. R. Robles J. Ocon C. F. Gomez M. Manjon L. Pastor J. Herrera J. Villatoro J. Calls J. Torrijos V. I. Rodríguez M. M. A. Rodriguez M. L. Mendez A. Morey F. I. Martinez J. Marco A. Liebana B. Rincon F. Tornero |
| author_facet | N. R. Robles J. Ocon C. F. Gomez M. Manjon L. Pastor J. Herrera J. Villatoro J. Calls J. Torrijos V. I. Rodríguez M. M. A. Rodriguez M. L. Mendez A. Morey F. I. Martinez J. Marco A. Liebana B. Rincon F. Tornero |
| author_sort | N. R. Robles |
| collection | DOAJ |
| description | Aim. To evaluate the safe use of a new calcium channel blocker, lercanidipine, in patients with chronic renal failure (CRF); the protective effect of calcium channel blocker on renal function in CRF patients previously treated with ACE inhibitors or angiotensin receptor blockers (ARB). Material and methods. The study included 203 CRF patients (creatinine >1,4 mg/dL for men, >1,2 mg/dL for women; or creatinine clearance <70 mL/min). All patients were receiving ACE inhibitors (63,4 %) or angiotensin II antagonist (36,6 %) therapy, but they had higher blood pressure than recommended for CRF (130/85 mmHg). No patients received diuretics. Patients were clinically evaluated 1, 3, and 6 months after starting treatment with lercanidipine. Urine and blood samples were taken during the examination. When needed, a third drug was added to the treatment, excluding diuretics. Creatinine clearance was measured using 24 h urine collection. Results. 175 patients completed the study protocol (age 63,9±11,9 years, 52,9 % males and 47,1 % females). Blood pressure (BP) significantly decreased from 162±17/93±8.3 mm Hg to 132±12/78±6 mm Hg. 89,2 % of patients showed a significant BP reduction, and 58,1 % achieved optimal BP control (<130/85 mmHg). Seven patients (3,4 %) showed adverse effects. No single case of oedema was detected, and the prevalence of adverse effects related to vasodilatation was extremely low (3 patients, 1,48 %). Plasmatic creatinine did not change (1,9±0,5 baseline vs.1,9±0,6 mg/dL), but creatinine clearance increased at the end visit (41,8±16,0 baseline vs. 45,8±18,0 mL/min, p=0,019). Plasmatic cholesterol also decreased from 221±46 to 211±35 mg/dL (p=0,001). Conclusion: Lercanidipine showed a high antihypertensive effect in CRF patients. It had a good tolerability profile and showed an interesting effect on plasmatic lipids. An improvement in renal function, assessed by creatinine clearance, was detected. |
| format | Article |
| id | doaj-art-109c1f5329dd4d4cb33091a4db84d439 |
| institution | DOAJ |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2010-08-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-109c1f5329dd4d4cb33091a4db84d4392025-08-20T02:59:53Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252010-08-019481871817Lercanidipine in patients with chronic renal failure: the ZAFRA StudyN. R. Robles0J. Ocon1C. F. Gomez2M. Manjon3L. Pastor4J. Herrera5J. Villatoro6J. Calls7J. Torrijos8V. I. Rodríguez9M. M. A. Rodriguez10M. L. Mendez11A. Morey12F. I. Martinez13J. Marco14A. Liebana15B. Rincon16F. Tornero17Unidad de HTA, Hospital Infanta Cristina, BadajozFundación Puigvert, BarcelonaHospital Gregorio Marañón, MadridHospital Clínico, GranadaHospital Miguel Servet, ZaragozaHospital General de Asturias, OviedoHospital General de Castellón, Castellón de la PlanaHospital Fundación de Manacor, MenorcaHospital Fundación de Manacor, MenorcaHospital Severo Ochoa, Leganes, MadridHospital La Inmaculada, Huercal-Overa, AlmeriaHospital Nuestra Señora de la Candelaria, TenerifeClinica Miramar, BarcelonaHospital de Galdacano, BilbaoHospital Son Dureta, MallorcaHospital Ciudad de Jaen, JaenHospital Virgen de la Luz, CuencaHospital Virgen de la Luz, CuencaAim. To evaluate the safe use of a new calcium channel blocker, lercanidipine, in patients with chronic renal failure (CRF); the protective effect of calcium channel blocker on renal function in CRF patients previously treated with ACE inhibitors or angiotensin receptor blockers (ARB). Material and methods. The study included 203 CRF patients (creatinine >1,4 mg/dL for men, >1,2 mg/dL for women; or creatinine clearance <70 mL/min). All patients were receiving ACE inhibitors (63,4 %) or angiotensin II antagonist (36,6 %) therapy, but they had higher blood pressure than recommended for CRF (130/85 mmHg). No patients received diuretics. Patients were clinically evaluated 1, 3, and 6 months after starting treatment with lercanidipine. Urine and blood samples were taken during the examination. When needed, a third drug was added to the treatment, excluding diuretics. Creatinine clearance was measured using 24 h urine collection. Results. 175 patients completed the study protocol (age 63,9±11,9 years, 52,9 % males and 47,1 % females). Blood pressure (BP) significantly decreased from 162±17/93±8.3 mm Hg to 132±12/78±6 mm Hg. 89,2 % of patients showed a significant BP reduction, and 58,1 % achieved optimal BP control (<130/85 mmHg). Seven patients (3,4 %) showed adverse effects. No single case of oedema was detected, and the prevalence of adverse effects related to vasodilatation was extremely low (3 patients, 1,48 %). Plasmatic creatinine did not change (1,9±0,5 baseline vs.1,9±0,6 mg/dL), but creatinine clearance increased at the end visit (41,8±16,0 baseline vs. 45,8±18,0 mL/min, p=0,019). Plasmatic cholesterol also decreased from 221±46 to 211±35 mg/dL (p=0,001). Conclusion: Lercanidipine showed a high antihypertensive effect in CRF patients. It had a good tolerability profile and showed an interesting effect on plasmatic lipids. An improvement in renal function, assessed by creatinine clearance, was detected.https://cardiovascular.elpub.ru/jour/article/view/2108lercanidipinechronic renal failurehypertension |
| spellingShingle | N. R. Robles J. Ocon C. F. Gomez M. Manjon L. Pastor J. Herrera J. Villatoro J. Calls J. Torrijos V. I. Rodríguez M. M. A. Rodriguez M. L. Mendez A. Morey F. I. Martinez J. Marco A. Liebana B. Rincon F. Tornero Lercanidipine in patients with chronic renal failure: the ZAFRA Study Кардиоваскулярная терапия и профилактика lercanidipine chronic renal failure hypertension |
| title | Lercanidipine in patients with chronic renal failure: the ZAFRA Study |
| title_full | Lercanidipine in patients with chronic renal failure: the ZAFRA Study |
| title_fullStr | Lercanidipine in patients with chronic renal failure: the ZAFRA Study |
| title_full_unstemmed | Lercanidipine in patients with chronic renal failure: the ZAFRA Study |
| title_short | Lercanidipine in patients with chronic renal failure: the ZAFRA Study |
| title_sort | lercanidipine in patients with chronic renal failure the zafra study |
| topic | lercanidipine chronic renal failure hypertension |
| url | https://cardiovascular.elpub.ru/jour/article/view/2108 |
| work_keys_str_mv | AT nrrobles lercanidipineinpatientswithchronicrenalfailurethezafrastudy AT jocon lercanidipineinpatientswithchronicrenalfailurethezafrastudy AT cfgomez lercanidipineinpatientswithchronicrenalfailurethezafrastudy AT mmanjon lercanidipineinpatientswithchronicrenalfailurethezafrastudy AT lpastor lercanidipineinpatientswithchronicrenalfailurethezafrastudy AT jherrera lercanidipineinpatientswithchronicrenalfailurethezafrastudy AT jvillatoro lercanidipineinpatientswithchronicrenalfailurethezafrastudy AT jcalls lercanidipineinpatientswithchronicrenalfailurethezafrastudy AT jtorrijos lercanidipineinpatientswithchronicrenalfailurethezafrastudy AT virodriguez lercanidipineinpatientswithchronicrenalfailurethezafrastudy AT mmarodriguez lercanidipineinpatientswithchronicrenalfailurethezafrastudy AT mlmendez lercanidipineinpatientswithchronicrenalfailurethezafrastudy AT amorey lercanidipineinpatientswithchronicrenalfailurethezafrastudy AT fimartinez lercanidipineinpatientswithchronicrenalfailurethezafrastudy AT jmarco lercanidipineinpatientswithchronicrenalfailurethezafrastudy AT aliebana lercanidipineinpatientswithchronicrenalfailurethezafrastudy AT brincon lercanidipineinpatientswithchronicrenalfailurethezafrastudy AT ftornero lercanidipineinpatientswithchronicrenalfailurethezafrastudy |